Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
Autonomix Medical (NASDAQ: AMIX) announced the issuance of U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” which broadens protection for its autonomic nervous system (ANS) assessment technologies.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced the issuance of U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” which broadens protection for its autonomic nervous system (ANS) assessment technologies. The patent covers systems, devices and methods for monitoring physiologic signals to evaluate sympathetic and parasympathetic nervous system activity using multiple assessment techniques.
According to Autonomix, the intellectual property may support patient selection, procedural guidance, treatment feedback and post-treatment monitoring across a wide range of neuromodulation applications. The patented systems use advanced imaging, sensors and algorithms to analyze ANS activity and are aimed at precision-based diagnosis and treatment of diseases involving the peripheral nervous system, further expanding the company’s neuromodulation-focused IP portfolio.
Details
Market move: AMIX -12.06% in the Jul 23 session. U.S. patent issuance
On Jul 23, the day this news came out, AMIX closed 12.06% below the previous close. Argus tracked a peak move of +20.1% during that session. Argus tracked a trough of -22.4% from its starting point during tracking. Our momentum scanner recorded 27 alerts for this stock that day. That session’s volume was 8.1x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jul 23 session.
Key Figures
- U.S. Patent Number
- 12,471,776
- Newly issued patent titled “ANS Assessment Systems, Kits, and Methods”
Historical Context
-
U.S. patent expanded the neural sensing and therapeutic platform into urology.
-
$2.6 million warrant exercise proceeds accompanied by newly issued replacement warrants.
-
Canadian patent strengthened global protections for nerve-targeted therapies.
-
Preclinical evidence showed real-time detection of renal nerve activity changes.
-
A 1-for-21 reverse split reduced outstanding shares and changed the trading structure.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
autonomic nervous system medical
neuromodulation medical
electrophysiological signals technical
autonomic dysfunction medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications
THE WOODLANDS, TX, July 23, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,471,776, titled "ANS Assessment Systems, Kits, and Methods," further strengthening the Company's intellectual property portfolio supporting its proprietary autonomic nervous system technologies.
The newly issued patent broadly covers systems, devices and methods for monitoring physiologic signals to assess autonomic nervous system (ANS) activity, including technologies designed to evaluate sympathetic and parasympathetic nervous system function through multiple physiologic assessment techniques. The patent also encompasses technologies that may support patient selection, procedural guidance, treatment feedback and post-treatment monitoring across a broad range of neuromodulation applications.
"Our vision has always extended well beyond developing a single product. We are building a differentiated technology platform capable of transforming how physicians identify, target and treat diseases involving the peripheral nervous system," said Brad Hauser, Chief Executive Officer of Autonomix. "This newly issued patent further strengthens our innovation and technological foundation supporting that vision by protecting innovations designed to improve the precision and effectiveness of future nerve-targeted therapies. We believe Autonomix is establishing an increasingly valuable leadership position in one of the most exciting emerging areas of medical technology."
The patented technology includes systems capable of monitoring physiologic and electrophysiological signals using advanced imaging, sensors and algorithms to analyze autonomic nervous system activity. The innovations described in the patent have potential applications across numerous disease states associated with autonomic dysfunction and may provide valuable procedural feedback during nerve-targeted therapies.
The issuance of U.S. Patent No. 12,471,776 further expands Autonomix Medical's intellectual property portfolio, which continues to support the Company's differentiated technology platform focused on precision-based diagnosis and treatment of diseases involving the peripheral nervous system.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions, the versatility and scalability of the Company's platform technology, the potential for future clinical applications across multiple organ systems, the strength and scope of the Company's intellectual property portfolio, and the potential for the Company's patented technologies to support patient selection, procedural guidance and post-treatment monitoring across multiple neuromodulation applications.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.